Summary
The clinical outcome of rheumatoid arthritis patients treated long term with sulphasalazine or parenteral gold was studied. The rate of withdrawal from gold because of inefficacy was less frequent than that for patients receiving sulphasalazine. However, patients on sulphasalazine withdrew less frequently because of adverse reactions.
Similar content being viewed by others
References
Bax DE, Amos RS. Sulphasalazine: a safe, effective agent for prolonged control of rheumatoid arthritis. A comparison with sodium aurothiomalate. Annals of the Rheumatic Diseases 44: 194–198, 1985
Bird HA, Dixon JS, Pickup ME, Rhind VM, Lowe JR. A biochemical assessment of sulphasalazine in rheumatoid arthritis. Journal of Rheumatology 9: 36–45, 1982
McConkey B, Amos RS, Butler EP, Crockson RS, Crockson AP, Walsh L. Salazopyrin in rheumatoid arthritis. Agents and Actions 8: 438–441, 1978
McConkey B, Amos RS, Durham S, Forster PJG, Hubball S, Walsh L. Sulphasalazine in rheumatoid arthritis. British Medical Journal 280: 442–444, 1980
Neumann VC, Grindulis KA, Hubball S, McConkey B, Wright V. Comparison between penicillamine and sulphasalazine in rheumatoid arthritis. British Medical Journal 287: 1099–1102, 1983
Pullar T, Hunter JA, Capell HA. Sulphasalazine in rheumatoid arthritis: a double blind comparison of sulphasalazine with placebo and sodium aurothiomalate. British Medical Journal 287: 1102–1104, 1983
Author information
Authors and Affiliations
Additional information
Enteric-coated sulphasalazine was used in this study; marketed by Pharmacia Ltd as Salazopyrin® EN-tabs, Azulfidine® EN-tabs® (USA), Azulfidine RA® (Germany).
Rights and permissions
About this article
Cite this article
Bax, D.E., Amos, R.S. Sulphasalazine in the Long Term Management of Rheumatoid Arthritis. Drugs 32 (Suppl 1), 73–76 (1986). https://doi.org/10.2165/00003495-198600321-00016
Published:
Issue Date:
DOI: https://doi.org/10.2165/00003495-198600321-00016